SOX方案联合甲磺酸阿帕替尼治疗晚期不可手术切除胃癌的效果

Curative efficacy of SOX regimen combined with apatinib mesylate on advanced unresectable gastric cancer

目的探讨替吉奥+奥沙利铂(SOX)方案联合甲磺酸阿帕替尼治疗晚期不可手术切除胃癌的效果。方法抽取2017年1月至2021年6月呼和浩特市第一医院收治的晚期胃癌患者60例,按照治疗方案分为对照组和观察组,每组30例。对照组采用SOX方案,观察组采用SOX联合甲磺酸阿帕替尼方案。比较两组疗效、总生存期、无进展生存期、不良反应发生率以及治疗前后血清血管内皮生长因子(VEGF)水平。结果观察组总有效率(60.00%,18/30)高于对照组(33.33%,10/30),P<0.05。观察组总生存期、无进展生存期长于对照组(t=4.051、2.937,P<0.05)。两组不良反应发生率比较差异未见统计学意义(P>0.05)。治疗前,两组VEGF水平比较差异未见统计学意义(P>0.05);治疗后,观察组血清VEGF水平[(392.02±65.14)ng/L]低于对照组[(486.02±72.54)ng/L],P<0.05。结论晚期不可手术切除胃癌患者应用SOX联合甲磺酸阿帕替尼方案治疗,相比单项SOX方案,可提高疗效,使患者生存期延长,且不会明显增加不良反应。

Objective To investigate the curative efficacy of tiggio and oxaliplatin(SOX)combined with apatinib mesylate on advanced unresectable gastric cancer.Methods Sixty patients with advanced gastric cancer who were admitted to Hohhot First Hospital from January 2017 to June 2021 were selected and divided into control group and observation group according to the treatment plans,with 30 cases in each group.The control group was treated with SOX regimen,and the observation group was treated with SOX combined with apatinib mesylate.The efficacy,overall survival,progression-free survival,incidence of adverse reactions and serum vascular endothelial growth factor(VEGF)levels before and after treatment were compared between the two groups.Results The total effective rate in the observation group(60.00%,18/30)was higher than that in the control group(33.33%,10/30),P<0.05.The overall survival and progression-free survival of the observation group were longer than those in the control group(t=4.051,2.937;P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Before treatment,there was no significant difference in VEGF levels between the two groups(P>0.05);after treatment,the serum VEGF level in the observation group was(392.02±65.14)ng/L,lower than the(486.02±72.54)ng/L in the control group(P<0.05).Conclusions Compared with the SOX regimen alone,the application of SOX combined with apatinib mesylate in the treatment of advanced unresectable gastric cancer can improve the curative effect,and prolong the survival time of patients,and it will not significantly increase the adverse reactions.